thiotriazole

Thiotriazole is an experimental small molecule that acts as a potent and selective covalent inhibitor of the mitogen-activated protein kinases ERK1 and ERK2. Developed by researchers at the University of Texas at Austin, it distinguishes itself from traditional ATP-competitive inhibitors by targeting the D-recruitment site (DRS), a protein-protein interaction (PPI) docking site. Specifically, the compound forms a covalent bond with a highly conserved cysteine residue (Cys166 in ERK2) within the DRS, which disrupts the molecular recognition and engagement of ERK with its downstream substrates and regulators. This mechanism provides more than 100-fold selectivity over other MAP kinases such as JNK, p38, and ERK5. Preclinical studies have demonstrated that thiotriazole induces dose-dependent inhibition of ERK signaling and apoptosis in BRAF V600E mutant melanoma cell lines, including those with acquired resistance to standard BRAF and MEK inhibitors. In vivo xenograft models have shown that treatment with this compound can effectively block tumor growth.